Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Sting agonists

- PMLiVE

AbbVie to acquire Allergan for $63bn

Deal based on major cuts and diversified portfolio

- PMLiVE

AbbVie’s upadacitinib tops Humira again in arthritis trial

Firm says pipeline drug only JAK inhibitor to show superiority

- PMLiVE

Merck & Co adds to immunotherapy again with $773m Tilos buy

Specialises in TGFβ complex-targeting therapies

- PMLiVE

Keytruda begins pursuit of rivals in small cell lung cancer

Set for competition with Opdivo

- PMLiVE

So far so good for Amgen’s much-anticipated KRAS inhibitor

Promise to hit previously 'undruggable' target

- PMLiVE

AZ invests more in IO with Transgene oncolytic virus deal

Opportunity for combinations with IO pipeline

- PMLiVE

European approval for Skyrizi, hot on the heels of US

Welcome news, but can't replace $20bn Humira

- PMLiVE

Roche, AbbVie hit by clinical hold for Venclexta in myeloma

Safety concerns could hit blockbuster expectations

- PMLiVE

CHMP recommends new Keytruda dosing schedule

Will apply to eight indications across five tumour types

- PMLiVE

AbbVie and Boehringer’s psoriasis drug Skyrizi gets CHMP nod

Analysts say the drug could be a best-in-class candidate in the therapy area

- PMLiVE

AbbVie enters BCMA race with Teneobio deal

Agreement includes option to acquire TeneoOne

- PMLiVE

Trulicity’s ascent lifts Lilly

Diabetes treatment leads new product growth

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links